- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Cannabis Weekly Round-Up: US Sales to Reach US$35 Billion in 2023
A new study from a cannabis researcher shows encouraging future sales growth for the industry in the US.
US cannabis sales are now projected to cross US$35 billion in 2023 and reach US$71 billion per year by 2030.
Meanwhile, a leading multi-state operator (MSO) informed the market it will need more time to file its latest financial report.
Keep reading to find out more cannabis highlights from the past five days.
Cannabis sales to reach US$71 billion in 2030
New Frontier Data, a leading cannabis research firm, released new projections for the US cannabis market over the next decade.
“As more established markets across the country stabilize, the U.S. cannabis industry will be buoyed by new markets coming online,” Gary Allen, CEO of New Frontier Data, said as the firm released its latest US cannabis market report.
The executive said the growth of the US market is so strong that even if there were a slowdown, current estimates show the sector would still have a 9 percent compound annual growth rate through 2030.
“Inflation, high taxes and competing illicit markets are compounding price pressures in mature legal markets, and the potential for a recession will negatively impact cannabis consumer spending in the medium term,” Allen said.
Legal sales in the US reached US$30 billion in 2022, according to New Frontier Data's research.
Cannabis MSO delays release of financial results
American MSO Curaleaf Holdings (CSE:CURA,OTCQX:CURLF) told investors it will not release its financial results for the full 2022 year and fourth quarter on March 28, as was originally planned.
The firm blamed complexities surrounding the conversion of three years of financials from International Financial Reporting Standards to US Generally Accepted Accounting Principles.
“The Company requires additional time to complete its financial statements,” Curaleaf said in a statement.
The cannabis operator said it now expects to file its results within the month of April.
Cannabis company news
- Ayr Wellness (CSE:AYR.A,OTCQX:AYRWF)opened four new dispensaries in the Florida state market. The new additions push the number of storefronts managed by the company to 57 in the state.
- Acreage Holdings (CSE:ACRG.A.U,OTCQX:ACRHF)told investors it will delay its Q4 and full-year financial results. With little to no explanation, the firm said it will update investors again “in due course.”
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
The Beginner’s Guide to Investing in Biotech
Ready to invest in biotech? Our beginner's guide makes it simple to get started.
Download your investing guide today.
Learn About Exciting Investing Opportunities in the Biotech Sector
Your Newsletter Preferences
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.
Bryan is a Senior Editor with INN. After graduating from the Langara journalism program he did some freelance reporting with community newspapers in British Columbia. He initially wrote about the life science space for INN and now spends his time covering the marijuana market, from Canadian LPs to US-based companies, and the impact of this sector on investors.
Learn about our editorial policies.